Utepreva Launches Utepreva Endometrial Sampler to Support Early Diagnosis of Endometrial Cancer

Why It Matters

Early, accurate detection of endometrial cancer can lower mortality and reduce reliance on invasive procedures, offering clinicians a more efficient diagnostic tool.

Key Takeaways

• Utepreva Endometrial Sampler launches, availability October 2026.
• Single‑pass design combines sponge tip, suction plunger, and collection chamber.
• Enables cytology, histopathology, and molecular analysis from one sample.
• Preclinical tests showed statistically higher tissue capture versus comparator.
• FDA 510(k) clearance paves way for swift market entry.

Pulse Analysis

Endometrial cancer accounts for roughly 7% of all cancers diagnosed in women in the United States, with over 66,000 new cases expected annually. Early-stage disease is highly treatable, yet current diagnostic pathways—often involving dilatation and curettage or hysteroscopic biopsy—can be uncomfortable, costly, and sometimes yield insufficient tissue for comprehensive analysis. The need for a less invasive, high‑yield sampling method has become a focal point for both clinicians and device innovators seeking to improve screening efficiency and patient experience.

Utepreva’s Endometrial Sampler tackles these challenges with a three‑pronged approach. A soft sponge tip first absorbs endometrial tissue and fluid, while a plunger‑driven suction mechanism actively aspirates cells, minimizing loss. The collected material is then housed in a sealed chamber compatible with cytologic, histopathologic, and molecular assays, allowing a single specimen to support a full diagnostic work‑up. In preclinical studies conducted by Medical Murray, the device captured a statistically greater amount of simulated tissue and produced more uniform cellular disruption than a market comparator, suggesting superior diagnostic yield. FDA 510(k) clearance further validates its safety profile and accelerates the path to clinical adoption.

The sampler’s launch could reshape the endometrial cancer diagnostic market, which is projected to exceed $1 billion globally by 2028. By simplifying the sampling process and expanding the range of analyzable biomarkers, the device may enable earlier detection, reduce repeat procedures, and lower overall care costs. Gynecologists and pathology labs are likely to evaluate its integration into outpatient settings, while payers may view the technology as a cost‑effective alternative to traditional biopsies. As real‑world data emerge post‑launch, the device could also spur broader research into molecular profiling of endometrial lesions, further personalizing treatment pathways.